Billing Requirements for Intravitreal Injections. Financial Interest. Indications. Documentation. Documentation. Documentation

Similar documents
Financial Interest. Financial Interest. Minor Procedures. Modifier -25. Minor Procedures & Office Visits

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

Coding Terminology Getting Back To The Basics. Financial Interest. Getting Back To The Basics. Rose & Associates

Financial Interest. Common Issues Found in Audits. Scope of This Course. Issues With Patient Histories. Chief Complaints/HPI. Chief Complaints/HPI

Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding

Documentation Challenges

Medicare Reimbursement Challenges. Financial Interest. Overpayments. Overpayments. Overpayments. Overpayments

Clinically Significant Macular Edema (CSME)

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin

Advanced Retina Coding

Fundamentals of Retina Coding

Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

A Patient s Guide to Diabetic Retinopathy

Financial Disclosure. Understanding Global Surgery Rules. Does Insurance Cover Surgery? Course Objectives

Financial Disclosure. Modifiers Getting It Right! Modifiers. Modifiers. Medicare Expected Frequency. Common Modifiers Used Only with Office Visits

Financial Interest Medicare Update. Physician Fee Schedule. Physician Fee Schedule. Physician Fee Schedule. Physician Fee Schedule

2009 REIMBURSEMENT GUIDE, VISUCAM and VISUCAM NM/FA

Intravitreal Injection

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Report for EYEGENETIX. Prepared on. May 24, By: David Davis, CPC, CPC-H, CCC (Ret.)

Eye injection treatment costs and rebates

The Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS

OCT Angiography The Next Frontier

Eye injection treatment costs and rebates

CORRECT RECORD KEEPING = CORRECT CODING (AND MORE)- PART II

Diabetic Retinopatathy

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

Financial Disclosure. Compliance Report. Course Objective. Issue 1: Complex Cataract Surgery. Compliance Dilemmas. What did I do wrong?

Vascular Endothelial Growth Factor (VEGF) Inhibitors Ocular Use Drug Class Monograph (Medical Benefit)

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.

Introduction How the eye works

The Foundation WHAT IS THE RETINA?

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.

Eylea (aflibercept) Document Number: IC-0026

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

Agenda. Financial Disclosure. Membrane Peel Codes. The Dilemma vs Membrane Peel codes 67041, 67042

Learn Connect Succeed. JCAHPO Regional Meetings 2015

Patient AB. Born in 1961 PED

1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures

Venous Occlusive Diseases

OCT Interpretation. Financial Disclosure. Jay M. Haynie, OD, FAAO. OCT Image Layers 7/21/2014

Contractor Information

Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

The Foundation WHAT IS THE RETINA? continued next page. RETINA HEALTH SERIES Facts from the ASRS

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Technicians & Nurses Program

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

EPIRETINAL MEMBRANE & VITREOMACULAR TRACTION

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012

NANOS. Diagnosing and Treating Neuro-Ophthalmology Coding Problems AMERICAN ACADEMY OF OPHTHALMIC EXECUTIVES AMERICAN ACADEMY OF OPHTHALMOLOGY

Ask the AOA Coding Experts: Vision versus Medical? Doug Morrow, O.D. Harvey Richman, O.D. Rebecca Wartman, O.D.

What is Age-Related Macular Degeneration?


Implementing New & Revised ICD-10 Codes

Case : The glaucoma consult Case: The Glaucoma Consult Case: The Glaucoma Consult Case : The Glaucoma Consult Case : The weekend call you don t want

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Prevalence and causes of macular edema and its correlation: an observational study

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

Do You See What I See!!! Shane R. Kannarr, OD

Reporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer.

Retinal Diseases. Age-Related Macular Degeneration. What Is AMD? Risk Factors for AMD

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431)

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431)

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

Optometric Postoperative Cataract Surgery Management

An Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences

Macular edema (ME) is the most common

*Pleasesee amendment forpennsylvaniamedicaid at the endofthis CPB.

Brampton Hurontario Street Brampton, ON L6Y 0P6

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014

Counseling to Prevent Tobacco Use

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION

Treatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection

Financial Disclosures

Facts About Diabetic Eye Disease

Mark T. Dunbar Disclosures. Hot Topics in Retina. The Challenge. Where is the Fluid? 4/12/2016

Age-Related Macular Degeneration (AMD)

Diabetic Retinopathy A Presentation for the Public

RETINAL CONDITIONS RETINAL CONDITIONS

The Economic$ and Epidemiology of Intravitreal Injections

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *

2/6/2018. Andrew Siedlecki, M.D.

Unexplained visual loss in seven easy steps

Information for patients

ZEISS AngioPlex OCT Angiography Overview ZEISS OCT Angiography

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

Course # Getting to Know Your OCT

Transcription:

Billing Requirements for Intravitreal Injections Financial Interest ASCRS ASOA Symposium & Congress Practice Management Program Los Angeles, California May 5-9, 2017 Presented by: Patricia Kennedy, COMT, CPC, CPMA, COE I acknowledge a financial interest in the subject matter of this presentation. Indications Exudative Macular Degeneration Diabetic Retinopathy Vascular Occlusive Disease Endophthalmitis/Uveitis Cystoid Macular Edema Obtaining Chief Complaint Coverage of eye examination is based on purpose of the exam, not on findings Without complaint, exam is not covered even though doctor discovers a pathological condition Must document Why is the patient here today? 3 4 Obtaining Chief Complaint If history is missing a chronic illness being followed, or a patient symptom, Medicare would determine visit routine, cosmetic or refractive and therefore not covered Obtaining Chief Complaint Beware of : Pt. here for recheck Pt. presents for 1 mo. Follow-up Pt. here for injection No changes since last visit Vision is about the same since the last injection 5 6 Rose & Associates 1 800 720 9667 1

Obtaining the Chief Complaint Acceptable CCs Pt. referred for evaluation of ARMD Pt. complains of blurry vision Pt. complains of distorted vision Pt. returns for follow-up of ARMD Pt. presents for 6 wk. re-check of BRVO The History of Present Illness (HPI), Personal Family & Social History PFSH can further describe the patient s problem Level of Exam Exam extent is based on the patient CC & HPI Performing/Billing all elements every time the patient is seen will not hold up in post-payment payment review. This is especially problematic with EMR Testing Order, interpretation and report 7 8 Assessment Condition being addressed Severity of the condition Location of the condition Avoid atypical abbreviations Plan Intravitreal Injection What medication When is it planned Which eye What is the prognosis improve, stabilize Avoid atypical abbreviations 9 10 Consent Patient identity Date of service Which eye What medication Avoid abbreviations IVA, Inj One may cover series of injections Check with malpractice carrier Advanced Beneficiary Notice (ABN) Complete all sections Patient name & identification number Description of what may not be covered Reason Medicare may not pay Estimated cost Beneficiary option checked Beneficiary signature Specific to procedure, supply & date Modifier -GA 11 12 Rose & Associates 1 800 720 9667 2

Advanced Beneficiary Notice (ABN) Used when a normally covered service may not be covered Drug is off-label Drug is experimental Frequency is outside expected Diagnosis isn t included on the LCD list Append Modifier -GA Pre-operative preparation Betadine, anesthetic Medication details Name, Lot #, Expiration date Location of injection eye & placement Amount injected Presence or absence or complications Post-operative instructions planned RTO 13 14 CPT code 67028- Intravitreal injection of a pharmacologic agent (separate procedure) Separate procedure commonly carried out as an integral component of a total service Minor Procedures are Defined by Global Periods of 0 or 10 days Listed in the Physician Fee Schedule 67028 0 days global period 15 16 Universally bundled Office Visit Typically Denied Modifier -25 appended to office visit Both services likely l paid Would payment withstand post-payment review? Does it meet the requirements of Modifier -25? Does not apply to tests Modifier -25 Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Same Day of the Procedure or Other Service Same Physician includes all physicians within a group practice 17 18 Rose & Associates 1 800 720 9667 3

Modifier -25 It may be necessary to indicate that on the day a procedure or service identified by a CPT code was performed, the patient s condition required a significant, separately identifiable E/M service above and beyond the other service provided or associated with the procedure that was performed. Modifier -25 Note: This modifier is not used to report an E/M service that resulted in a decision to perform surgery See Modifier -57 Modifier -57 applies to major surgery not minor surgeries or procedures 19 20 Modifier -25 does NOT apply to new patients for Medicare Doesn t hinder processing if applied RACs don t always know this rule May be required by commercial carriers New patient is defined as any patient who has not been seen in the practice in the previous 3 years Justification of exam with modifier -25 Patient complaint reflects symptoms that may or may not be related to the minor procedure The exam is required to determine cause Be sure the patient issue is addressed in the documentation Exam, assessment and plan 21 22 Modifier -25 is an area of interest for the Office of Inspector General Is expected to be rare occurrence in overall billing profile of a practice Particularly visible in single subspecialty practices such as a retina practice Modifier -25 can be used to separate an exam from a minor procedure Must be above & beyond what would typically be done for the pre-op & post-op op for the procedure If you remove the exam related to the procedure do you have anything left? It should be rare 23 24 Rose & Associates 1 800 720 9667 4

Medications Avastin (Bevacizumab) Off-label J3490, J3590, J9035 or J7999 Lucentis (Ranibizumab) Contractor discretion J2778 Macugen (Pegaptanib) Contractor discretion J2503 Eylea (Aflibercept) Contractor discretion J0178 Medications Jetrea (Ocriplasmin) - Contractor discretion J7316 Kenalog (Triamcinolone acetonide) J3301 Triesence (Preservative free triamcinolone) J3300 25 26 CPT Code 65800 - Paracentesis of anterior chamber of eye (separate procedure); with removal of aqueous Performed prophylactically to prevent a pressure spike Preventative measures not covered Therefore not billable same time as injection DO NOT BILL Tests Diagnostic Testing SCODI CPT 92134 (bilateral) Fundus photography CPT 92250 (bilateral) Fluorescein angiography CPT 92235 (unilateral) Indocyanine Green angiography CPT 92240 (unilateral) FA & ICG CPT 92242 B-Scan CPT 76512 (unilateral) 27 28 Tests Diagnostic Testing Physician Order Physical test results or location of test Separate interpretation and report Tests Diagnostic Testing Physician services Extended ophthalmoscopy CPT 92225/92226 (Unilateral) Gonioscopy CPT 92020 (Bilateral) 29 30 Rose & Associates 1 800 720 9667 5

Example #1- Visit #1 NP referred for eval of macular degeneration L>R. C/O blurry VA x 3 mos unable to read. Exam: Wet Macular Degeneration LT > RT OCT = CS Macular Thickening Plan: Lucentis Injection OS today- Op Note found under Procedures RTC 4 wks Mac OCT & possible injection OS Example #1 Visit #1 9xx0x 92134 67028-LT J2778 ICD-10 diagnosis code H35.3231 New patient exam warranted Modifier -25 unnecessary 31 32 Example #1 Visit #2 4 wk f/up Lucentis injection & Mac OCT Exam: Wet Macular Degeneration LT > RT OCT = CS Macular Thickening Plan: Lucentis Injection OS today- Op Note found under Procedures RTC 4 wks Mac OCT & possible injection OS Example #1 Visit #2 92134 67028-LT J2778 ICD-10 diagnosis code H35.3231 No exam charge No separate service No cc or HPI 33 34 Example #1 Visit #3 Pt returns for re-eval of ARMD, Mac OCT & possible Lucentis inj. OS. Last Inj. 1 mo ago. Exam: Wet Macular Degeneration LT > RT OCT = CS Macular Thickening Plan: Lucentis Injection OS today- Op note found under procedures Return 4 wks possible injection OS Example #1 Visit #3 92134 67028 J2778 ICD-10 diagnosis code H35.3231 Exam is specific to the injection Possible injection implies decision for injection will be made at the time of exam Modifier -25 does not apply 35 36 Rose & Associates 1 800 720 9667 6

Example #1 Visit #4 Pt returns for re-evaluation of ARMD & Mac OCT. Pt c/o ++ floaters OS since last injection 1 mo ago. Denies flashes. Exam: Wet Macular Degeneration OU. Vitreous floaters OS w/o ret tear, hole or detachment OCT = CS Macular Thickening OS > OD Plan: Lucentis Injection OS & Mac OCT Example #1 Visit #4 CPT Code 9xxxx-25 CPT Code - 92134 CPT Code - 67028 HCPCS Code - J2778 ICD-10 Code H43.392 & H35.3231 Patient presents with new complaint reflects extended exam of entire retina, not just macula Patient CC was addressed 37 38 Example #1 Visit #5 Pt here for Injection #4 Exam: Wet Macular Degeneration OU OCT = CS Macular Thickening Plan: Injection Today Example #1 Visit #5 92134 (as long as there is an order & I&R) ICD-10 diagnosis code H35.3231 No complaint or chronic illness in the CC or HPI No details for the procedure 39 40 Example #2 Pt. returns 3 mos early. C/O sudden LOV RT. IDDM Type 2.?controlled. LBS 192 A1c unknown. Exam: PDR RT >LT with macular edema FP Scattered MAs FA Macular edema RT > LT, NVE, MAs Gonio- No NVI. Open to CB. Plan: Avastin injection OD Today ABN Op note under procedures + A/C Tap Example #2 9xxxx-25 92250 92235 92020 67028-RT J3590-GA ICD-10 diagnosis code E11.3513 A/C Tap was done to prevent IOP from rising. Preventative not billable. 41 42 Rose & Associates 1 800 720 9667 7

Questions Rose & Associates 1-800-720-9667 results@roseandassociates.com www.roseandassociates.com Rose & Associates 1 800 720 9667 8